Hims & Hers Health Inc. Aktie News

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.

My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Europe, offering geographic diversification. The featured stocks all show significant undervaluation potential based on rather conservative growth scenarios.

Amazon's cost-cutting could supercharge its profitability. Hims & Hers has explosive long-term growth potential.

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United Kingdom which will include drugs like Novo Nordisk's Wegovy, the company said on Wednesday.

LONDON--(BUSINESS WIRE)--Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care. Sixty four percent of UK adults are overweight or living with obesity, yet access...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification beyond GLP-1s, reducing regulatory and competitive risks. By assuming very achievable growth rates, the company seems to be undervalued by up to 102%.

Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate successful European expansion and accelerate subscriber growth. GLP-1 weight-loss treatments drive revenue potential but introduce margin pressure and cost volatility, creating both opportunity and struct...

US-based digital health company Hims & Hers Holdings Inc (NYSE:HIMS) is entering the Canadian market following its acquisition of Livewell, a Canadian telehealth platform focused on weight loss and other wellness services. The move positions Hims & Hers to launch a Canadian weight loss program in 2026, coinciding with the availability of the first generic semaglutide.